Stratification of responders towards eculizumab using a structural epitope mapping strategy.

about

Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization.Staphylococcus carnosus: from starter culture to protein engineering platform.

P2860

Q36364687-F9E3EFD0-670A-48C0-8128-F5A1E48BFCA0 Q46056256-5AB818CA-151F-4C2F-9657-D048FCB76C33

P2860

Stratification of responders towards eculizumab using a structural epitope mapping strategy.

Item

http://www.wikidata.org/entity/Q42364725

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Stratification of responders t ...... ural epitope mapping strategy.

@en

Stratification of responders t ...... ural epitope mapping strategy.

@nl

type

Item

label

Stratification of responders t ...... ural epitope mapping strategy.

@en

Stratification of responders t ...... ural epitope mapping strategy.

@nl

prefLabel

Stratification of responders t ...... ural epitope mapping strategy.

@en

Stratification of responders t ...... ural epitope mapping strategy.

@nl

P1476

Stratification of responders t ...... ural epitope mapping strategy.

@en

P2093

Anna-Luisa Volk

http://www.w3.org/2001/XMLSchema#string

Erik Nordling

http://www.w3.org/2001/XMLSchema#string

Francis Jingxin Hu

http://www.w3.org/2001/XMLSchema#string

Johan Rockberg

http://www.w3.org/2001/XMLSchema#string

Magnus M Berglund

http://www.w3.org/2001/XMLSchema#string

Patrik Strömberg

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated map of genetic variation from 1,092 human genomes

Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex

Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene

dbSNP: the NCBI database of genetic variation

The Structure of OMCI, a Novel Lipocalin Inhibitor of the Complement System

Structure of and influence of a tick complement inhibitor on human complement component 5

Structural basis for therapeutic inhibition of complement C5

Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

P2888

srep31365

P304

31365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP31365

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mathias Uhlén

P577

2016-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27509843

http://www.w3.org/2001/XMLSchema#string

P932

4980765

http://www.w3.org/2001/XMLSchema#string

Stratification of responders towards eculizumab using a structural epitope mapping strategy.

about

P2860

P2860

Stratification of responders towards eculizumab using a structural epitope mapping strategy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P932